Paratek announces inclusion of NUZRYA in China’s NRDL

Paratek Pharmaceuticals (PRTK) announced that China’s National Healthcare Security Administration has added the intravenous formulation of NUZYRA to the country’s National Reimbursement Drug List for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, resulting in millions of patients gaining access to the broad-spectrum, once daily antibiotic. NUZYRA was granted approval by the U.S. Food and Drug Administration in October 2018 and Paratek initiated the U.S. product launch in February 2019. Paratek’s partner in China, Zai Lab Limited(ZLAB) received approval of both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration of China for the treatment of CABP and ABSSSI in December 2021.